Molecular Partners AG
NASDAQ:MOLNBiotechnology
Healthcare
$2.67 +0.77%
+$0.03 today
- Market cap
- $100.28M
- Beta
- 0.71
- P/E (TTM)
- -2.0
- EPS (TTM)
- -$1.55
52W Low $3.41High $5.36
Volume 0.00M
Average 0.00M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$51.26M
FY 2025 · Annual
Investing Cash Flow
$72.55M
FY 2025 · Annual
+79.2% YoYFinancing Cash Flow
-$1.15M
FY 2025 · Annual
Cash Flow Statement
CHF
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (63.79M) | 117.85M | (61.98M) | (54.04M) | (61.65M) |
| Depreciation & Amortization | 2.57M | 2.39M | 2.42M | 2.37M | 2.14M |
| Deferred Income Tax | 2K | 0 | 0 | 2K | 2K |
| Stock-Based Compensation | 4.09M | 5.09M | 5.21M | 4.11M | 4.42M |
| Change in Working Capital | (34.67M) | (6.01M) | (6.01M) | (3.8M) | 1.16M |
| Accounts Receivables | (23.37M) | 25.26M | (933K) | (347K) | 463.2K |
| Inventory | 21.72M | (19.93M) | 0 | 0 | 0 |
| Accounts Payables | 1.66M | (5.34M) | (812K) | 524K | 62.08K |
| Other Working Capital | (34.67M) | (6.01M) | (4.27M) | (3.97M) | 630.33K |
| Other Non-Cash Items | 848K | (753K) | 1.36M | (7.88M) | 2.67M |
| Operating Cash Flow | (90.95M) | 118.57M | (59.01M) | (59.25M) | (51.26M) |
| Capital Expenditures | (1.31M) | (1.42M) | (575K) | (723K) | (714K) |
| Acquisitions (Net) | 374K | 0 | 0 | 0 | 0 |
| Purchases of Investments | (88.88M) | (299.42M) | (277.83M) | (240.05M) | (66.28M) |
| Sales of Investments | 67.88M | 199.22M | 319.44M | 277.02M | 137.81M |
| Other Investing Activities | (304K) | 494K | 3.83M | 4.22M | 1.73M |
| Investing Cash Flow | (22.24M) | (101.12M) | 44.64M | 40.49M | 72.55M |
| Debt Repayment | (1.18M) | (1.19M) | (1.2M) | (1.21M) | (1.21M) |
| Common Stock Issued | 51.49M | 250K | 31K | 17.34M | 63K |
| Common Stock Repurchased | 0 | (631K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 267K | 250K | 31K | (1.7M) | 0 |
| Financing Cash Flow | 50.58M | (1.57M) | (1.17M) | 14.43M | (1.15M) |
| Effect of Forex Changes | 701K | 258K | (5.1M) | 894K | (1.36M) |
| Net Change in Cash | (61.91M) | 16.13M | (20.64M) | (3.44M) | 18.78M |
| Free Cash Flow | (92.26M) | 117.15M | (59.81M) | (59.97M) | (51.97M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$61.7M
+ D&A$2.1M
+ Stock-Based Comp$4.4M
+ Deferred Tax$2.0K
+ Working Capital$1.2M
+ Other Non-Cash$2.7M
= Operating Cash Flow-$51.3M
- Capex-$714.0K
= Free Cash Flow-$52.0M
Analysis
FY2025 free cash flow is -$52.0M. FCF conversion is 84.3% of net income. Operating cash flow was -$51.3M, with capex of -$714.0K. The largest bridge item is Stock-Based Comp at $4.4M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Oct 29, 2026 | |
| 6-K | 6-K filing | Aug 25, 2026 | |
| 6-K | 6-K filing | Jul 20, 2026 | |
| 6-K | 6-K filing | Jul 7, 2026 | |
| 6-K | 6-K filing | Jul 2, 2026 |
Does MOLN generate free cash flow?
Molecular Partners AG (MOLN) generated -$51.97M of free cash flow in fiscal 2025.
How much operating cash flow does MOLN produce?
Operating cash flow was -$51.26M, before capital expenditures of $714,000.00.
Continue the stock analysis
Jump to another research area for this company.